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Abstract
Background: Toll-like receptor 4 (TLR4) is a key innate immunity receptor that initiates an inflammatory response. Growing
evidence suggests that mutation of TLR4 gene may play a role in the development of cancers. This study aimed to
investigate the temporal relationship of single nucleotide polymorphisms of TLR4 and the risk of hepatocellular carcinoma,
a single center-based case-control study was conducted.
Methods: A systematic genetic analysis of sequence variants of TLR4 by evaluating ten single-nucleotide polymorphisms
was performed from 216 hepatocellular carcinoma cases and 228 controls.
Results: Six single nucleotide polymorphisms of the TLR4 in the 59-untranslated region and intron were associated with risk
of hepatocellular carcinoma. Individuals carrying the heterozygous genotypes for the rs10759930, rs2737190, rs10116253,
rs1927914, rs12377632 and rs1927911 had significantly decreased risk of hepatocellular carcinoma (adjusted odds ratio [OR],
from 0.527 to 0.578, P,0.01) comparing with those carrying wild-type homozygous genotypes. In haplotype analysis, one
haplotype (GCCCTTAG) of TLR4 was associated significantly with decrease of the occurrence of hepatocellular carcinoma
(OR, 0.556, 95% confidence interval [CI], 0.407–0.758, P=0.000).
Conclusions: Collectively, these results suggested that the risk of hepatocellular carcinoma was associated with TLR4
sequence variation. TLR4 single nucleotide polymorphisms may play an important protective role in the development of
hepatocellular carcinoma.
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Introduction
Toll-like receptors (TLRs) are a group of highly conserved molecules
that allow the immune system to sense molecules that are present in
most classes of pathogens. The recognition of pathogen associated
molecular patterns (PAMPs) by TLRs is a cornerstone of innate
immunity and provides a quick and highly efficient response to
pathogens. Much of the evidence supports a role for TLR-mediated
signaling in inflammation. TLR4 is located on chromosome 9, and
exposure to bacterial products or pro-inflammatory cytokines increases
TLR4 expression in monocytes and polymorphonuclear leukocytes
[1]. The occurrence of TLR4 activation is confirmed during the
systemic inflammatory response [2–4]. TLR4-deficient mice showed
lower response to viral and bacterial infection than did wild-type mice
[5], which suggested that TLR4 activation pathway can initiate innate
immune responses to both bacterial and viral pathogens.
Emerging evidence from association investigations has shown
that TLR4 polymorphisms are associated with chronic and
recurrent inflammation and the occurrence of related cancer [6].
Recently, several studies showed that variants in TLR4 were
related with the risk of prostate cancer in Eastern Asian population
[7] or Western population [8],[9]. In other studies, TLR4
polymorphism increases risk of gastric carcinoma [10] and its
precursors [11]. However, there has not been any investigation
about TLR4 polymorphisms in hepatocellular carcinoma yet.
Healthy liver contains low gene transcription of TLR4 and its
adaptor molecules such as CD14, myeloid differentiation protein-2
(MD-2) and myeloid differentiation factor 88 (MyD88) [12].
However, under pathologic conditions, TLR4 activates inflam-
matory-signaling pathways in the liver and is actively involved in
the pathophysiology in some hepatic diseases including Hepatitis B
virus (HBV) [13]. HBV is a DNA virus that causes an acute
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chronic in the remaining 10–20% of adult patients. Chronic
hepatitis B is the leading cause of hepatic cirrhosis and
hepatocellular carcinoma [14]. Hepatocellular carcinoma is the
fifth most common cancer worldwide and the third leading cause
of cancer-related death, with more than half the cases occurring in
China [15]. Notably, most hepatocellular carcinoma cases in
China are associated with chronic hepatitis B virus (HBV)
infection [16].
In light of the strong biological support for a role for TLR4 in
carcinogenesis and the potential importance of inflammation and
inflammatory genes in hepatocellular carcinoma development, we
hypothesized that single-nucleotide polymorphisms of TLR4 are
associated with hepatocellular carcinoma susceptibility. To test
this hypothesis, we performed a systematic genetic analysis in a
Chinese population hospital-based hepatocellular carcinoma case-
control study.
Results
The selected characteristics of the hepatocellular carcinoma
cases and control subjects are summarized in Table 1. There were
no significant differences between patients with hepatocellular
carcinoma and controls in terms of age, sex and HBV carriers
(P.0.05). Among hepatocellular carcinoma cases, a-FP level
higher than 400 ng/ml was in 33.1% of patients and a-FP below
400 ng/ml was in 66.9%. For UICC classification, 45.83% were
in tumor stage I to II and 54.17% in stage III–IV.
The observed genotype frequencies of all 10 polymorphisms in
both of patients and controls conformed to the Hardy-Weinberg
equilibrium (all P.0.05). The distributions of genotypes for TLR4
were shown in Table 2. Chi Square analysis of the genotypes
revealed significantly different distributions in six TLR4 SNPs
(rs10759930, rs2737190, rs10116253, rs1927914, rs10759932 and
rs1927911) between the group with hepatocellular carcinoma and
the control group (P,0.05). Among them, five SNPs were located
in the 59-UTR of TLR4 gene while one SNP was located in the
region of intron.
Table 3 presented the association between TLR4 variants and
hepatocellular carcinoma risk. Individuals carrying the heterozy-
gous genotypes for the rs10759930, rs2737190, rs10116253,
rs1927914, rs12377632 and rs1927911 were associated signifi-
cantly with decreased risk of hepatocellular carcinoma comparing
with those carrying wild-type homozygous genotypes (adjusted
odds ratio [OR] by sex and age, from 0.527 to 0.578, P,0.01).
Eight of ten TLR4 SNPs were located in 1 haplotype block, and
the magnitude of LD between each SNP was extremely high, with
pair-wise D’.0.9 (Figure 1). Furthermore, the haplotype analysis
was performed for evaluating the frequencies of haplotypes based
on the 8 polymorphisms within the block, trying to derive
haplotypes specifically correlated with the risk of hepatocellular
carcinoma. Four common TLR4 haplotypes (frequency .1%)
were found with the accumulated frequency of 90.03% in controls
Table 1. Baseline characteristics of hepatocellular carcinoma
cases and controls.
Cases n (%) Controls n (%) P Value
Number 216 228
Mean age (yr) 54.3612.4 47.2613.7
Age group
#55 123 (56.94%) 153 (67.11%) 0.299
.55 93 (40.06%) 75 (32.89%)
Sex
Male 182 (84.26%) 184 (80.7%) 0.273
Female 33 (15.74%) 44 (19.3%)
HBV carriers
Yes 177 (81.94%) 181 (77.2%) 0.074
No 39 (18.06%) 47 (22.8%)
a-FP level
.400 ng/ml 82 (33.1%) NA
,400 ng/ml 134 (66.9%)
UICC classification
Stage I–II 99 (45.83%) NA
Stage III–IV 117 (54.17%)
a-FP: alpha-fetoprotein; NA: no data.
doi:10.1371/journal.pone.0019466.t001
Table 2. Genotype frequencies of TLR4 single nucleotide
polymorphisms.
SNP Location Genotype
Cases, n
(%)
Controls, n
(%) P Value
rs10759930 59-UTR TT 90 (41.67) 70 (30.70) 0.039
CT 89 (41.20) 118 (51.75)
CC 37 (17.13) 40 (17.54)
rs2737190 59-UTR AA 95 (43.98) 73 (32.02) 0.025
AG 87 (40.28) 118 (51.75)
GG 34 (15.74) 37 (16.23)
rs10116253 59-UTR TT 98 (45.37) 74 (32.46) 0.019
CT 87 (14.35) 116 (50.88)
CC 31 (40.28) 38 (16.67)
rs1927914 59-UTR TT 94 (43.52) 74 (32.46) 0.034
CT 87 (40.28) 118 (51.75)
CC 35 (16.20) 36 (15.79)
rs10759932 59-UTR TT 130 (60.19) 110 (48.25) 0.040
CT 70 (32.41) 98 (42.98)
CC 16 (7.41) 20 (8.77)
rs1927911 Intron CC 92 (42.59) 72 (31.58) 0.040
CT 90 (41.67) 120 (52.63)
TT 34 (15.74) 36 (15.79)
rs12377632 Intron CC 91 (42.13) 78 (34.21) 0.202
CT 90 (41.67) 112 (49.12)
TT 35 (16.20) 38 (16.67)
rs2149356 Intron CC 93 (43.06) 77 (33.77) 0.119
AC 89 (41.20) 113 (49.56)
AA 34 (15.74) 38 (16.67)
rs11536889 39-UTR GG 123 (56.94) 123 (53.95) 0.518
CG 76 (35.19) 91 (33.91)
CC 17 (7.87) 14 (6.14)
rs7037117 39-UTR AA 122 (56.48) 123 (53.95) 0.739
AG 74 (34.26) 86 (37.72)
GG 20 (9.26) 19 (8.33)
P value was calculated by a x
2–test 362 contingency table (df =2).
doi:10.1371/journal.pone.0019466.t002
A Pilot Study
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between cases and controls was not significant (Pglobal =0.061).
The haplotype GCCCTTAG was associated significantly with
decrease of the risk of the occurrence of hepatocellular carcinoma
(OR, 0.556, 95% CI, 0.407–0.758, P=0.048) when compared
with the most common haplotype ATTTCCCG.
Table 5 shows FPRP estimates for selected results of seven SNPs
and one haplotype of TLR4. The association for six TLR4 SNPs
showed a FPRP below 0.200, which suggested that thess
associations are unlikely to represent a false-positive result. For
associations with TLR4 haplotype, the association also yielded a
FPRP below 0.200.
Discussion
There is growing evidence that TLR4 genetic polymorphisms
impact on risk of cancer including gastric cancer [10] and prostate
cancer [8]. TLR4 plays a central role in the signaling pathways
that control the innate immune response in response to viral or
bacterial infection. TLR4 was up-regulated in the hepatocytes in
patients with chronic hepatitis B [17]. Patients with chronic
hepatitis B infection will eventually progress into liver cirrhosis and
hepatocellular carcinoma [18]. We hypothesized that single-
nucleotide polymorphisms of TLR4 are related to the occurrence
of hepatocellular carcinoma. In this study, the genetic diversity in
TLR4 was examined comprehensively to validate our hypothesis
that inherited differences in TLR4 were associated with hepato-
cellular carcinoma. To our knowledge, this is the first attempt to
investigate a series of common SNPs located in the TLR4 gene in
patients with hepatocellular carcinoma.
Activation of TLR4 can cause liver injury under several clinical
conditions such as hemorrhagic shock [19], hepatic ischemia
reperfusion injury [20], alcohol hepatitis [21] and chronic hepatitis
B [17]. Experimental investigations revealed that TLR4 gene
mutations were associated with low response to viral and bacterial
infection and therefore led to a reduction in the innate immune
response and inflammation. The missense mutation in the third
exon of TLR4 rendered the C3H/HeJ and C57B/10ScCr mice
resistant to the toxic effects of LPS from Gram-negative bacteria
[22]. TLR4 mutant (C3H/HeJ) mice subjected to trauma had less
Table 3. Association between hepatocellular carcinoma and TLR4 single nucleotide polymorphisms.
SNP Genotype Odd Ratio (95% CI) P Value Odd Ratio (95% CI) { P Value
rs10759930 TT 1 1
CT 0.587 (0.387–0.889) 0.012 0.550 (0.360–0.839) 0.006
CC 0.719 (0.417–1.241) 0.237 0.660 (0.379–1.148) 0.141
rs2737190 AA 1 1
AG 0.567 (0.375–0.855) 0.007 0.529 (0.348–0.805) 0.003
GG 0.706 (0.405–1.232) 0.220 0.626 (0.354–1.106) 0.107
rs10116253 TT 1 1
CT 0.566 (0.376–0.854) 0.007 0.527 (0.347–0.800) 0.003
CC 0.616 (0.351–1.081) 0.091 0.553 (0.312–0.981) 0.043
rs1927914 TT 1 1
CT 0.580 (0.385–0.876) 0.010 0.547 (0.360–0.830) 0.005
CC 0.765 (0.439–1.335) 0.346 0.684 (0.387–1.207) 0.190
rs10759932 TT 1 1
CT 0.604 (0.406–0.900) 0.013 0.578 (0.386–0.865) 0.008
CC 0.677 (0.335–1.370) 0.278 0.609 (0.298–1.246) 0.175
rs1927911 CC 1 1
CT 0.587 (0.389–0.886) 0.011 0.544 (0.358–0.829) 0.005
TT 0.739 (0.422–1.295) 0.291 0.661 (0.373–1.172) 0.157
rs12377632 CC 1 1
CT 0.689 (0.457–1.038) 0.075 0.651 (0.429–0.987) 0.043
TT 0.789 (0.456–1.368) 0.399 0.719 (0.411–1.258) 0.248
rs2149356 CC 1 1
AC 0.652 (0.433–0.983) 0.041 0.607 (0.400–0.921) 0.019
AA 0.741 (0.426–1.287) 0.287 0.655 (0.378–1.168) 0.155
rs11536889 GG 1 1
CG 0.835 (0.563–1.238) 0.370 0.848 (0.570–1.260) 0.413
CC 1.214 (0.573–2.571) 0.612 1.336 (0.626–2.851) 0.454
rs7037117 AA 1 1
AG 0.868 (0.582–1.293) 0.485 0.842 (0.563–1.259) 0.402
GG 1.061 (0.540–2.086) 0.863 1.019 (0.516–2.013) 0.957
OR, odds ratio; 95% CI, 95% confidence interval;
{Adjusted for age and sex. P value was calculated by a x
2–test 262 contingency table (df =1).
doi:10.1371/journal.pone.0019466.t003
A Pilot Study
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[23]. TLR4 mutant mice display natural resistance to acid-
induced acute lung injury [24].
Our results in this study suggested that inherited variation in TLR4
influences the risk of hepatocellular carcinoma. Specifically, we firstly
described the positive association between four 59-UTR polymor-
phism (rs10759930, rs2737190, rs10116253 and rs1927914) and one
intron polymorphism (rs1927911) of TLR4 gene and the risk of
hepatocellular carcinoma. There is a significantly decreased risk of
hepatocellular carcinoma in individuals carrying the heterozygous
genotypes for the rs10759930, rs2737190, rs10116253, rs1927914,
rs12377632 and rs1927911 when comparing with those carrying
wild-typehomozygousgenotypes(OR,from0.527to0.578,P,0.01).
Among these positive SNPs in the present study, rs10759930,
rs2737190, rs10116253, rs1927914 and rs12377632 were located in
59-UTR. Cheng et al [25] found that there is a significantly increased
riskofprostate cancer inindividualscarryingthe variant homozygous
genotype for rs10759932 located in 59-UTR when comparing with
those carrying wild-type homozygous genotypes. In another study by
Chen et al [9], homozygosity for the variant alleles of rs10116253 was
associated with a statistically significant lower risk of prostate cancer.
Our results suggested that mutation of TLR4 gene in 59-UTR might
reduce the occurrence of hepatocellular carcinoma. Although the
observed two-fold decrease in risk is modest, our finding is intriguing
because genes in multiple pathways alter the risk for hepatocellular
carcinoma, and each individual gene is likely to contribute only a
modest risk. The 59-UTRs polymorphisms of TLR4 presumably
affect transcription and/or translation among individuals with
hepatocellular carcinoma. As 59-UTRs influence the translation of
regulatory proteins during growth, differentiation, embryonic
development, and stress, modulation of 59-UTR activity plays a role
in the development or progress of specific forms of cancer. In most
cases, the 59-UTR is involved in the regulated expression of a key
protein concerning with growth or differentiation innormal tissues.A
Figure 1. Linkage disequilibrium plot of ten SNPs of the TLR4 gene in patients with hepatocellular carcinoma. D’ corresponding to
each SNP pair are expressed as a percentage and shown within the respective square. Higher D’ is indicated by a brighter red.
doi:10.1371/journal.pone.0019466.g001
Table 4. Association of haplotypes in TLR4 with hepatocellular carcinoma.
Haplotype Control Frequency{ Case Frequency{ OR (95% CI) Pglobal P Value
0.061
ATTTCCCG 35.3 30.7 1.042 (0.788–1.378) 0.772
ATTTCCCC 22.5 21.6 0.921 (0.670–1.265) 0.611
GCCCTTAG 20.2 28.3 0.556 (0.407–0.758) 0.000
GCCTTTAG 11.9 9.9 1.083 (0.708–1.655) 0.713
OR, odds ratio; 95% CI, 95% confidence interval;
{, proportion of indicated haplotype (%). P value was calculated by a x
2–test 262 contingency table (df =1).
doi:10.1371/journal.pone.0019466.t004
A Pilot Study
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neoplastic transformation [26]. In our study, the TLR4 SNPs may
potentially exert regulator effects and therefore might decrease the
risk for hepatocellular carcinoma. Due to the strong regional
correlation across TLR4, these SNPs may serve as a proxy for the
predisposing variants or the polymorphism themselves may have
functional consequences on TLR4 expression or signaling activity.
Alteration in TLR4 activity influences innate immunity and
inflammation, which in turn may affect hepatocellular carcinoma
susceptibility. Functional assays are needed to elucidate the
molecular mechanisms underlying these associations. In addition,
only individuals carrying heterozygous genotypes have a decrease
for the risk of hepatocellular carcinoma development in our study.
Such situation is not usual but is observed in some investigations of
other cancers, such as esophageal squamous cell carcinoma [27],
pancreatic cancer [28], and breast cancer [29,30]. Gene coding
sequences account for only 1.5% of the human genome. Subtotal
association studies have largely focused onknown coding sequences.
However, there are accumulating evidences that mutations in the
splice, donor and acceptor sites or enhancer, intron and promoter
elements may be important in genetic expression and regulation
[31]. Some investigations have found that genetic SNPs within are
involved in tumorigenesis, including prostate cancer [32], breast
cancer [33] and other cancers [34],[35]. In the present study, three
SNPs (rs1927911), which located in the region of intron of TLR4,
appeared to decrease risk of hepatocellular carcinoma (OR, from
0.572 to 0.607, P,0.01) significantly also. In the investigation by
Chen et al [9], the risk of prostate cancer was lower significantly in
individuals carrying variant carriers in rs1927911 (OR, 0.63, 95%
CI, 0.41–0.95).
LD analysis showed that the eight TLR4 SNPs were in high LD and
located in one haplotype block. Individuals carrying haplotype
GCCCTTAG may decrease the risk of hepatocellular carcinoma
significantly (OR, 0.556, 95% CI, 0. 0.407–0.758, P=0.000)
compared to those who carried the most common haplotype
ATTTCCCG. These results indicate that the TLR4 SNPs commonly
linked to the GCCCTTAG haplotype are likely to be protective.
In conclusion, our study provided evidence of a close association
between TLR4 sequence variants and hepatocellular carcinoma.
Although the contribution of the SNPs in TLR4 is modest, these
sequence variations, together with haplotype, may define a genetic
susceptibility background for hepatocellular carcinoma, suggesting
that TLR4 gene variation may play an important protective role in
the occurrence of hepatocellular carcinoma. More studies are
needed to validate this finding in independent populations and to
understand the mechanism by which TLR4 sequence variants
affect the pathological role of TLR4 in the signaling pathways that
control carcinogenesis.
Materials and Methods
Case-control study cohorts
In total, this case-control study consisted of 216 patients with
hepatocellular carcinoma (hepatocellular carcinoma) from Ruijin
Hospital, Shanghai Jiaotong University Medical School were
enrolled and 228 non cancer control. All patients and controls
were unrelated Han Chinese and gave informed consent. The study
protocol was approved by the independent ethics committee of
Ruijin Hospital, Shanghai Jiaotong University Medical School. The
content was written. The case study patients were enrolled
consecutively from June 2008 to June 2010 at Ruijin Hospital,
Shanghai Jiaotong University Medical School. All cases were newly
diagnosed, previously untreated (chemotherapy or transcatheter
arterial chemoembolization, TACE). HCC was diagnosed by the
elevation of alpha-fetoprotein (.400 ng/ml) or by pathological
examination in combination with the results of examination of
iconography including computer tomography (CT) and magnetic
resonance imaging (MRI). Clinical classification was dependent of
the results of CT or MRI according to International Union Against
Cancer (UICC) tumor-node-metastasis (TNM) staging system [36].
The patients with hepatocellular carcinoma were proved not to
have otherkinds ofcancer CT, MRIorpositron emissioncomputed
tomography (PET-CT). In addition, these subjects included in this
investigation were negative for antibodies to hepatitis C virus,
hepatitis D virus and had no other types of liver disease (for
example, autoimmune hepatitis, toxic hepatitis, and primary biliary
cirrhosis or Budd-Chiari syndrome). The option of treatments for
hepatocellular carcinoma includes hepatectomy, liver transplanta-
tion, chemotherapy or/and TACE. HBV carriers were defined as
positive for both hepatitis B surface antigen and antibody
immunoglobulin G to hepatitis B core antigen. In order to reduce
the confounding effect of HBV infection in research of genetic
susceptibility to HCC, controls were randomly selected from the
individuals who attended hepatitis examination in the hospital
during the period of case collection. The selection criteria for the
Table 5. FPRPs for the selected associations between genetic polymorphisms and hepatocellular carcinoma.
SNP or Odd Ratio Observed P value Prior probability
Haplotype (95% CI) 0.25 0.1 0.01 0.001
SNP
rs10759930 0.587 (0.387–0.889) 0.012 0.0666 0.1762 0.7018 0.9596
rs2737190 0.567 (0.375–0.855) 0.007 0.0391 0.1087 0.5730 0.9312
rs10116253 0.566 (0.376–0.854) 0.007 0.0386 0.1074 0.5697 0.9304
rs1927914 0.580 (0.385–0.876) 0.010 0.0546 0.1476 0.6557 0.9505
rs10759932 0.604 (0.406–0.900) 0.013 0.0735 0.1922 0.7236 0.9635
rs1927911 0.587 (0.389–0.886) 0.011 0.0630 0.1678 0.6893 0.9572
rs2149356 0.652 (0.433–0.983) 0.041 0.1981 0.4256 0.8907 0.9880
Haplotype
GCCCTTAG 0.556 (0.407–0.758) 0.000 0.0012 0.0037 0.0391 0.2910
OR, odds ratio; 95% CI, 95% confidence interval.
doi:10.1371/journal.pone.0019466.t005
A Pilot Study
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cancer at the time of ascertainment and frequency matching to the
patients on age and gender.
Selection of TLR4 Single-Nucleotide Polymorphisms
The subsets of reported TLR4 SNPs were determined by using
publicly available genotype data from the International HapMap
project (http://hapmap.ncbi.nlm.nih.gov/index.html.zh). We do-
wnloaded the data for TLR4 SNPs that spanned ,2 kb upstream
of the TLR4 transcription start site and ,1 kb downstream of the
39-untranslated region (UTR). Ten SNPs were selected by using
the criteria of minor allele frequencies (MAF) $5% in Chinese
people population, including the predicted 59- UTR, the introns
and the predicted 39- UTR. An important goal in this study was to
evaluate common haplotypes of TLR4 sequence variants with use
of a limited number of TLR4 SNPs. SNPs located in exons
and promoter regions were excluded from the study because
MAF of all these SNPs was lower than 5% in Chinese people
population.
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes.
The genomic regions of interest were amplified by multiplex
polymerase chain reactions (PCRs). These PCR reactions were
performed in a total volume of 10 ml containing 20 ng DNA, 3 m
mol dNTPs, 1X PCR Gold buffer with 28 m mol MgCl2,4m mol
of each primer and 0.5 unit of Hotstar HiFidelity DNA
Polymerase (Qiagen,German). Samples were denatured at 95uC
for 15 min followed by 15 cycles of 94uC for 40 s, 63uC for 60 s,
followed by 72uC for 1.5 min, followed by 20 cycles of 94uC for
40 s, 56uC for 40 s, followed by 72uC for 1.5 min, and a final
extension at 72uC for 8 min.
All ten SNPs were genotyped by SNaPshot Multiplex kit
(Applied Biosystems, Foster City, CA, USA). In brief, 15 mlo f
mixed PCR products from the above reactions were then
incubated with 2 U of shrimp alkaline phosphatase (SAP) and
2 U of exonuclease I/(Exo I) at 37uC overnight, followed by
heating at 75uC for 15 min to inactivate SAP and Exo I. Following
this, 10 ml of reaction mix included 5 ml of SNaPshot reaction mix,
3 ml of pooled PCR products. 1 ml of pooled SNaPshot primers
and 1 ml of deionized water were incubated in a GeneAmp 9600
thermal cycler by 25 cycles at 96uC for 10 s, 50uC for 5 s, and
60uC for 30 s, and finally 60uC for 30 s. Then, 1 U of SAP and
1 U CIP (calf intestinal phosphatase) was added to SNaPshot
product and incubated at 37uC for an hour to deactivate the
enzyme. SNaPshot product was diluted for 20 times. The final
reaction mix containing 8.6 ml of Hi-Di Formamide, 0.5 mlo f
SNaPshot product and 0.9 ml of GeneScan-120 LIZ internal size
standard (Applied Biosystems) was denatured at 95uC 5 min.
Samples were placed at 220uC for storage prior to electropho-
resis. The genotypes of 13 SNPs were identified by different
fluorescent signals by ABI-3730XL Genetic Analyzer (Applied
Biosystems). The conditions of electrophoresis were according to
the guildlines by Applied Biosystems. The data were analyzed by
the software of GeneMapper 4.0.
Genotype analysis was performed in a blinded manner so that
the staff was unaware of the cases or control status. For quality
control, a 10% masked random sample of cases and controls was
tested repetitively by different investigators and all the results were
completely concordant.
Statistical Analysis
Data were expressed as proportions or mean and standard
deviation (SD). All these tests were performed with the SPSS 13.0
version for Windows. All reported P values were two sided.
Grouped data were compared by the Mann-Whitney U test.
The Hardy-Weinberg equilibrium (HWE) test using two-sided
x
2 analysis was done for each SNP among cases and controls.
Genotype frequency differences were tested between hepatocellu-
lar carcinoma group and control group were tested for each SNP
by two-sided x
2 test with 2 degrees of freedom.
Odds ratios (ORs) of hepatocellular carcinoma for the variant-
allele carriers (homozygous and heterozygous) versus homozygous
wild-type allele carriers were estimated by unconditional logistic
regression and adjusted for age (#55 or .55).
Haplotype block structure and the estimates of pair-wise linkage
disequilibrium (LD) (D’) were determined by using Haploview
software (http://www.broadinstitute.org/haploview/haploview/
index.php). Haplotype frequency was estimated with the statistical
method by implementing the computer program PHASE. A
global score test was used to assess the difference in haplotype
frequency distributions between cases and controls. Association
between the haplotypes and hepatocellular carcinoma was
performed with the x
2 test.
False-positive report probabilities (FPRPs) for those associations
observed to be statistically significant (P,0.05) were calculated to
account for potential false positives because some associations
would arise by chance. FPRP is defined as the probability of no
true association between genetic variants and disease given the
statistically significant finding. The values of false-positive report
probability (FPRP) were assessed by the use of method described
by Wacholder et al [37]. We assumed prior probabilities for
associations with hepatocellular carcinoma status under a
dominant model of 0.1 for each SNP and 0.01 for each
haplotype. FPRP ,0.200 was considered to indicate a noteworthy
association.
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